• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Antitumor activity of novel N-sulfonylpyrimidine derivatives on the growth of anaplastic mammary carcinoma in vivo.新型N-磺酰基嘧啶衍生物对间变性乳腺癌体内生长的抗肿瘤活性。
J Cancer Res Clin Oncol. 2005 Dec;131(12):829-36. doi: 10.1007/s00432-005-0026-z. Epub 2005 Nov 15.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
4
Greater antitumor efficacy of paclitaxel administered before epirubicin in a mouse mammary carcinoma.在小鼠乳腺癌模型中,紫杉醇在表柔比星之前给药具有更强的抗肿瘤效果。
J Cancer Res Clin Oncol. 1998;124(5):236-44. doi: 10.1007/s004320050160.
5
Corticosteroids for the treatment of Duchenne muscular dystrophy.用于治疗杜氏肌营养不良症的皮质类固醇
Cochrane Database Syst Rev. 2016 May 5;2016(5):CD003725. doi: 10.1002/14651858.CD003725.pub4.
6
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
7
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.单独及与传统抗癌药物联合使用的9-氯-2-甲基玫瑰树碱醋酸盐对人脑肿瘤异种移植瘤治疗的临床前评估。
J Cancer Res Clin Oncol. 1998 Jan;124(1):19-26. doi: 10.1007/s004320050128.
8
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂(GLP-1 RAs)减肥效果的网状Meta分析的数量、质量及结果:一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
9
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.伯氨喹或其他8-氨基喹啉用于减少恶性疟原虫传播。
Cochrane Database Syst Rev. 2015 Feb 19(2):CD008152. doi: 10.1002/14651858.CD008152.pub4.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.

引用本文的文献

1
Mass spectrometry and theoretical studies on N-C bond cleavages in the N-sulfonylamidino thymine derivatives.N-磺酰脒基胸腺嘧啶衍生物中N-C键断裂的质谱分析及理论研究
J Am Soc Mass Spectrom. 2015 May;26(5):833-42. doi: 10.1007/s13361-014-1068-8. Epub 2015 Mar 12.
2
In vivo toxicity study of N-1-sulfonylcytosine derivatives and their mechanisms of action in cervical carcinoma cell line.N-1-磺酰胞嘧啶衍生物的体内毒性研究及其在宫颈癌细胞系中的作用机制。
Invest New Drugs. 2012 Jun;30(3):981-90. doi: 10.1007/s10637-011-9657-x. Epub 2011 Mar 22.

本文引用的文献

1
Thymidylate synthase: a critical target in cancer therapy?胸苷酸合成酶:癌症治疗中的关键靶点?
Front Biosci. 2004 Sep 1;9:2467-73. doi: 10.2741/1408.
2
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.氟尿嘧啶四十年的持续创新:氟尿嘧啶化放疗的当前与未来方法
J Clin Oncol. 2004 Jun 1;22(11):2214-32. doi: 10.1200/JCO.2004.08.009.
3
A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.早期乳腺癌患者同步环磷酰胺/甲氨蝶呤/5-氟尿嘧啶与减量放疗的前瞻性研究。
Cancer. 2004 Apr 1;100(7):1358-64. doi: 10.1002/cncr.20136.
4
The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer.5-氟尿嘧啶前体药物5'-脱氧-5-氟尿苷与环磷酰胺联合口服化疗用于转移性乳腺癌的潜力。
Br J Cancer. 2003 Nov 3;89(9):1627-32. doi: 10.1038/sj.bjc.6601350.
5
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.卡培他滨(希罗达)在日本和高加索乳腺癌患者中的药代动力学。
Cancer Chemother Pharmacol. 2003 Sep;52(3):193-201. doi: 10.1007/s00280-003-0642-8. Epub 2003 May 29.
6
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.一项可手术乳腺癌序贯辅助化疗的III期试验:10年随访的最终分析
Cancer. 2003 Jun 1;97(11):2716-23. doi: 10.1002/cncr.11396.
7
Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.卡培他滨:晚期乳腺癌治疗中其药理学与治疗效果的综述
Drugs. 2003;63(2):217-36. doi: 10.2165/00003495-200363020-00009.
8
Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.环磷酰胺、甲氨蝶呤和5-氟尿嘧啶同步化疗及放疗用于乳腺癌:一种耐受性良好的辅助治疗方案。
Cancer. 2002 Aug 15;95(4):696-703. doi: 10.1002/cncr.10744.
9
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.5-氟尿嘧啶的三种口服前体药物(卡培他滨、优福定、S-1)的临床研究:综述
Oncologist. 2002;7(4):288-323. doi: 10.1634/theoncologist.7-4-288.
10
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.一项随机试验,比较环磷酰胺、甲氨蝶呤和5-氟尿嘧啶(CMF)与交替使用CMF、表柔比星和长春新碱作为可手术乳腺癌的一线化疗方案。
Cancer. 2002 Jul 15;95(2):228-35. doi: 10.1002/cncr.10678.

新型N-磺酰基嘧啶衍生物对间变性乳腺癌体内生长的抗肿瘤活性。

Antitumor activity of novel N-sulfonylpyrimidine derivatives on the growth of anaplastic mammary carcinoma in vivo.

作者信息

Pavlak Marina, Stojković Ranko, Radacić-Aumiler Matea, Kasnar-Samprec Jelena, Jercić Jure, Vlahović Ksenija, Zinić Biserka, Radacić Marko

机构信息

Department of Biology, Faculty of Veterinary Medicine, Zagreb University, Heinzelova 55, 10000, Zagreb, Croatia.

出版信息

J Cancer Res Clin Oncol. 2005 Dec;131(12):829-36. doi: 10.1007/s00432-005-0026-z. Epub 2005 Nov 15.

DOI:10.1007/s00432-005-0026-z
PMID:16158306
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12161197/
Abstract

PURPOSE

The purpose of this study was to investigate in vivo antitumor activity of newly synthesized N-sulfonylpyrimidine derivatives 1-(p-toluenesulfonyl)cytosine (4H), 1-(p-toluenesulfonyl)cytosine hydrochloride (4HxHCl) and zinc(II) complex of 1-(p-toluenesulfonyl)cytosine (4K).

MATERIALS AND METHODS

In order to do that we have used mouse anaplastic mammary carcinoma (AMCa). Tumor cells (10(6)) in a volume of 0.02 ml were transplanted into the thigh of the right hind leg of CBA mice. All compounds were dissolved in distilled water immediately before injecting to animals.

RESULTS

Antitumor effect of these compounds depends on drug doses and time interval between tumor transplantation and drug application. Further the efficacy of these compounds depends on number of drug injections, i. e. whether drug was given in single or in multiple doses. Multiple doses of 400 mg/kg of 1-(p-toluenesulfonyl)cytosine (4H) showed good antitumor effect when applied on day 1, 3, 5, 7 and 9 after tumor transplantation. Still good but slightly lower antitumor effect was also achieved when that compound was given in a single dose (1,200 mg/kg) on day 1 after tumor transplantation. The longest period of tumor growth time was obtained after application of 1-(p-toluenesulfonyl)cytosine hydrochloride (4HxHCl) given as a single dose (300 mg/kg) on day 1 or on day 6 after tumor implantation. However, antitumor effect of zinc(II) complex of 1-(p-toluenesulfonyl)cytosine (4K) was very strong when 300 mg/kg was given on day 1 or day 6, while this effect was slightly lower when drug (200 mg/kg/inj) was given on day 1, 3, 5, 7 and 9 or on day 6, 8, 10, 12 and 14.

CONCLUSION

In this work it has been found that N-1-sulfonylcytosine derivatives have strong antitumor activity against mouse mammary carcinoma which is a good reason for further research of these compounds both in experimental and preclinical studies.

摘要

目的

本研究旨在调查新合成的N-磺酰基嘧啶衍生物1-(对甲苯磺酰基)胞嘧啶(4H)、1-(对甲苯磺酰基)胞嘧啶盐酸盐(4HxHCl)和1-(对甲苯磺酰基)胞嘧啶锌(II)配合物(4K)的体内抗肿瘤活性。

材料与方法

为了进行此项研究,我们使用了小鼠间变性乳腺癌(AMCa)。将体积为0.02 ml的肿瘤细胞(10⁶个)移植到CBA小鼠右后腿的大腿中。所有化合物在注射给动物之前立即溶解于蒸馏水中。

结果

这些化合物的抗肿瘤作用取决于药物剂量以及肿瘤移植与药物应用之间的时间间隔。此外,这些化合物的疗效还取决于药物注射次数,即药物是单次给药还是多次给药。在肿瘤移植后的第1、3、5、7和9天应用多次剂量的400 mg/kg的1-(对甲苯磺酰基)胞嘧啶(4H)显示出良好的抗肿瘤效果。当该化合物在肿瘤移植后的第1天单次给药(1200 mg/kg)时,也获得了良好但略低的抗肿瘤效果。在肿瘤植入后的第1天或第6天单次给药(300 mg/kg)的1-(对甲苯磺酰基)胞嘧啶盐酸盐(4HxHCl)后,获得了最长的肿瘤生长时间。然而,当在第1天或第6天给予300 mg/kg的1-(对甲苯磺酰基)胞嘧啶锌(II)配合物(4K)时,其抗肿瘤作用非常强,而当在第1、3、5、7和9天或第6、8、10、12和14天给予药物(200 mg/kg/次注射)时,这种作用略低。

结论

在这项工作中发现,N-1-磺酰基胞嘧啶衍生物对小鼠乳腺癌具有很强的抗肿瘤活性,这是在实验和临床前研究中进一步研究这些化合物的充分理由。